Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Favipiravir. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.31 |
| ▸ | AKT1 | P31749 | 1/20 | 0.31 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Favipiravir SCHEMBL587913 | 0.87 | LCK (0.34) | LMNA | |
| Favipiravir SCHEMBL30725561 | 0.85 | LCK (0.33) | — | |
| Favipiravir SCHEMBL21085196 | 0.85 | LCK (0.33) | — | |
| Favipiravir SCHEMBL28952948 | 0.74 | PARP1 (0.38) | — | |
| SCHEMBL31259490 | 0.73 | PLAU (0.33) | LMNA | |
| SCHEMBL5269681 | 0.73 | PLAU (0.33) | LMNA | |
| SCHEMBL24146634 | 0.72 | NPSR1 (0.47) | HSD17B10 | |
| SCHEMBL28169294 | 0.72 | PDPK1 (0.36) | LMNA | |
| SCHEMBL24068727 | 0.72 | DGAT1 (0.39) | LMNAHPGD | |
| SCHEMBL6376447 | 0.71 | KMT2A (0.32) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115677602-A | Refining method of Favipiravir | 浙江华海药业股份有限公司 | 2023-02-03 | — | — | CN | disclosed |